New name reflects focus on accelerating portfolio of advanced ADC therapies with speed, agility and precision Upon closing of strategic transactions, cash expected ...

replacing the “AADI” symbol it’s held since going public in a 2021 merger with Aerpio Pharmaceuticals. The new name is aimed at better reflecting the biotech’s “evolution and focus on ...

Kaken assumes ownership of Aadi Sub, including the Aadi Bioscience name, trademarks and the FYARRO ® (sirolimus protein-bound particles for injectable suspension) (albumin-bound) business.

Upon the divestiture of Aadi's subsidiary to Kaken. Kaken will assume ownership of the Aadi name, trademark, and the FYARRO business. And today, Aadi Parent Company, relaunches as Whitehawk ...

Coronation Street's original Aadi Alahan has totally transformed since his days on the cobbles. The character is now played ...

Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments, today ...

Upon the divestiture of Aadi's subsidiary to Kaken. Kaken will assume ownership of the Aadi name, trademark, and the FYARRO business. And today, Aadi Parent Company, relaunches as Whitehawk ...

Upon the divestiture of Aadi’s subsidiary to Kaken. Kaken will assume ownership of the Aadi name, trademark, and the FYARRO business. And today, Aadi Parent Company, relaunches as Whitehawk ...

including the pending sale of Aadi Sub to Kaken and the payment of the upfront and early milestones under the Wuxi ADC agreement; the anticipated timing of the Company's development of its ...

Two Pakistani women sit together on a couch, rehearsing their lines while a director scrutinizes them. Waiting off camera for ...